| Identification | Back Directory | [Name]
YUM70 | [CAS]
423145-35-1 | [Synonyms]
YUM70
Butanamide, N-[1,3-benzodioxol-5-yl(5-chloro-8-hydroxy-7-quinolinyl)methyl]- | [Molecular Formula]
C21H19ClN2O4 | [MDL Number]
MFCD02228856 | [MOL File]
423145-35-1.mol | [Molecular Weight]
398.84 |
| Chemical Properties | Back Directory | [Boiling point ]
661.0±55.0 °C(Predicted) | [density ]
1.373±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (250.73 mM; Need ultrasonic) | [form ]
Solid | [pka]
14.74±0.46(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C21H19ClN2O4/c1-2-4-18(25)24-19(12-6-7-16-17(9-12)28-11-27-16)14-10-15(22)13-5-3-8-23-20(13)21(14)26/h3,5-10,19,26H,2,4,11H2,1H3,(H,24,25) | [InChIKey]
BIQMEYCMAGHOEQ-UHFFFAOYSA-N | [SMILES]
C(NC(C1=CC=C2OCOC2=C1)C1C(O)=C2C(=C(Cl)C=1)C=CC=N2)(=O)CCC |
| Hazard Information | Back Directory | [Uses]
YUM70 is a potent and selective inhibitor of glucose-regulated protein 78 (GRP78), with an IC50 of 1.5 μM for inhibiting GRP78 ATPase activity of the full-length protein. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer. YUM70 also has in vivo efficacy in a pancreatic cancer xenograft model[1]. | [Biological Activity]
YUM70 is a potent and selective inhibitor of glucose-regulated protein 78 (GRP78), with an IC50 of 1.5 μM for inhibiting GRP78 ATPase activity of the full-length protein. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer. YUM70 also has in vivo efficacy in a pancreatic cancer xenograft model[1].
YUM70 shows selective cytotoxicity for MIA PaCa-2, PANC-1, BxPC-3 cells (IC50=2.8, 4.5, and 9.6 μM, respectively) over normal pancreatic tissue-derived HPNE cells (IC50>30 μM)[1].YUM70 (5 μM; 24 h) induces endoplasmic reticulum (ER) stress-mediated apoptosis of MIA PaCa-2cells[1].
YUM70 (30 mg/kg; i.p. 5 days a week for 7 weeks) inhibits tumor growth in a MIA PaCa-2 xenograft model[1].YUM70 (15 mg/kg; i.v.) exhibits t1/2 (1.40 h), CL (724.04 mL/h/kg), and Vss (1162.73 mL/kg) in mice[1].YUM70 (30 mg/kg; p.o.) exhibits bioavailability (6.71%), t1/2 (2.74 h), and CL (9230.15 mL/h/kg) in mice[1]. | [in vivo]
YUM70 (30 mg/kg; i.p. 5 days a week for 7 weeks) inhibits tumor growth in a MIA PaCa-2 xenograft model[1].
?
YUM70 (15 mg/kg; i.v.) exhibits t1/2 (1.40 h), CL (724.04 mL/h/kg), and Vss (1162.73 mL/kg) in mice[1].
?
YUM70 (30 mg/kg; p.o.) exhibits bioavailability (6.71%), t1/2 (2.74 h), and CL (9230.15 mL/h/kg) in mice[1]. | Animal Model: | 8-week old female NCr nude mice were injected with MIA PaCa-2 cells[1] | | Dosage: | 30 mg/kg | | Administration: | I.p. 5 days a week for 7 weeks | | Result: | Observed a significant tumor growth delay with no significant change in body weight during the course of treatment. |
| [References]
[1]. Samanta S, et, al. The hydroxyquinoline analog YUM70 inhibits GRP78 to induce ER stress-mediated apoptosis in pancreatic cancer. Cancer Res. 2021 Feb 2;canres.1540.2020. |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|